Your browser doesn't support javascript.
loading
Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists
Camps-Herrero, C; Paz-Ares, L; Codes, M; López-López, R; Antón-Torres, A; Gascón-Vilaplana, P; Guillem-Porta, V; Carrato, A; Cruz-Hernández, JJ; Caballero-Díaz, C; Blasco-Cordellat, A; Moreno-Nogueira, JA; Díaz-Rubio, E.
Afiliación
  • Camps-Herrero, C; Universitat de Valencia. Valencia. Spain
  • Paz-Ares, L; Hospital Virgen del Rocío. Sevilla. Spain
  • Codes, M; Hospital Virgen Macarena de Sevilla. Sevilla. Spain
  • López-López, R; Complejo Universitario de Santiago de Compostela. Santiago de Compostela. Spain
  • Antón-Torres, A; Hospital Universitario Miguel Servet. Zaragoza. Spain
  • Gascón-Vilaplana, P; Hospital Clínico Universitario de Barcelona. Barcelona. Spain
  • Guillem-Porta, V; Fundación Instituto Valenciano de Oncología. Valencia. Spain
  • Carrato, A; Hospital Universitario Ramón y Cajal de Madrid. Madrid. Spain
  • Cruz-Hernández, JJ; Hospital Universitario de Salamanca. Salamanca. Spain
  • Caballero-Díaz, C; Hospital General Universitario de Valencia. Valencia. Spain
  • Blasco-Cordellat, A; Hospital General Universitario de Valencia. Valencia. Spain
  • Moreno-Nogueira, JA; Hospital Universitario Virgen del Rocío. Sevilla. Spain
  • Díaz-Rubio, E; Hospital Clínico San Carlos. Madrid. Spain
Clin. transl. oncol. (Print) ; 16(10): 914-920, oct. 2014.
Article en En | IBECS | ID: ibc-127611
Biblioteca responsable: ES1.1
Ubicación: BNCS
ABSTRACT
PURPOSE: The economic situation showed that the resources devoted to health spending are limited, making rationalisation of their consumption necessary. The relevance of pharmacoeconomic analyses is becoming crucial. The ECO Foundation, promoting the quality of oncology care, set out to analyse the consensus on the new therapeutic targets inclusion and the integration of pharmacoeconomics when evaluating their effectiveness. METHODS: Study about pharmacoeconomic estimations was performed during the first ECO-Seminar (2010). It was developed using a modified Delphi method, in four stages: (1) committee coordinator establishment, (2) expert-panel selection, (3) preparation and submission of survey (1 question) by email, and (4) analysis of the degree of consensus reached. RESULTS: Results were obtained from surveys completed by 35 experts. Regarding the tolerable annual cost for the approval of new drugs, 68.8 % of the respondents considered a cost per quality-adjusted life year (QALY) gained between 30,000 and 100,000 acceptable (34.4 % 30,000-60,000; 34.4 % 60,000-100,000), 21.9 % of the respondents found costs between 100,000-150,000/QALY and 9.3 % of the respondents found costs above 150,000/QALY acceptable. CONCLUSIONS: The costs of new drugs are higher than traditional treatments, making it a priority to identify subgroups of patients with specific molecular profiles as candidates for higher-efficiency-targeted therapies. The allocation of the available resources to the most effective interventions, to achieve the best clinical outcomes with lower costs and best subjective profile possible, allows expenditure to be rationalised. Pharmacoeconomic studies are a basic tool for obtaining better health outcomes according to the available resources, while also considering the other needs of the population (AU)
RESUMEN
No disponible
Asunto(s)
Buscar en Google
Añadir a Mi BVS
Imprimir
XML

Colección: 06-national / ES Base de datos: IBECS Asunto principal: Calidad de Vida / Servicio de Oncología en Hospital / Oncología Médica Tipo de estudio: Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Límite: Female / Humans / Male Idioma: En Revista: Clin. transl. oncol. (Print) Año: 2014 Tipo del documento: Article
Buscar en Google
Añadir a Mi BVS
Imprimir
XML

Colección: 06-national / ES Base de datos: IBECS Asunto principal: Calidad de Vida / Servicio de Oncología en Hospital / Oncología Médica Tipo de estudio: Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Límite: Female / Humans / Male Idioma: En Revista: Clin. transl. oncol. (Print) Año: 2014 Tipo del documento: Article